These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35569010)

  • 1. Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021.
    Maeda H; Uchida M; Kusano M; Tsukamoto K; Yamanoi M
    Clin Pharmacol Ther; 2022 Oct; 112(4):817-823. PubMed ID: 35569010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan.
    Hayashi H; Nogita T; Maeda H
    Patient Prefer Adherence; 2024; 18():1471-1479. PubMed ID: 39011090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.
    Wu J; Yang Y; Yu J; Qiao L; Zuo W; Zhang B
    Orphanet J Rare Dis; 2023 Nov; 18(1):368. PubMed ID: 38017575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded Access Allows for Compassionate Use of Investigational Cancer Drugs.
    Miller D
    ONS Connect; 2015 Jun; 30(2):47. PubMed ID: 26137830
    [No Abstract]   [Full Text] [Related]  

  • 6. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer.
    Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW
    Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing expanded access and compassionate use programs for experimental drugs.
    Miller JE; Ross JS; Moch KI; Caplan AL
    BMC Res Notes; 2017 Jul; 10(1):350. PubMed ID: 28754150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
    Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
    J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
    Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z
    PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.
    Hoerger M
    Death Stud; 2016; 40(2):113-20. PubMed ID: 26313583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded access to investigational drugs in psychiatry: A systematic review.
    Vermeulen SF; Polak TB; Bunnik EM
    Psychiatry Res; 2023 Nov; 329():115554. PubMed ID: 37890403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.
    Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y
    Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
    Finkelstein PE
    AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
    [No Abstract]   [Full Text] [Related]  

  • 15. Dilemmas in the compassionate supply of investigational cancer drugs.
    Lewis JR; Lipworth W; Kerridge I; Doran E
    Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
    Bunnik EM; Aarts N; van de Vathorst S
    Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should patients in need be given access to experimental drugs?
    Caplan AL; Bateman-House A
    Expert Opin Pharmacother; 2015 Jun; 16(9):1275-9. PubMed ID: 26001178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.
    Speers MA
    Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Food and Drug Administration responds to pressure for expanded drug access.
    Brower V
    J Natl Cancer Inst; 2014 Jun; 106(6):dju171. PubMed ID: 24907387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.